EPS and akathisia profile1,2
For schizophrenia in adults
Incidence of EPS* and akathisia were similar to placebo in 4- to 6-week trials1,2
Incidence of EPS and akathisia1,2
4- to 6-week trials
Proportion of patients (%) | CAPLYTA (n=406) | Placebo (n=412) |
|---|---|---|
EPS (including akathisia) | 6.7% | 6.3% |
Akathisia | 2.0% | 2.9% |
4- to 6-week trials
Proportion of patients (%) | CAPLYTA (n=372) | Placebo (n=374) |
|---|---|---|
EPS (including akathisia) | 6.7% | 6.3% |
Akathisia | 2.0% | 2.9% |
Changes in movement scores were similar to placebo in 4- to 6-week trials1†
Change in movement scores from baseline1†
4- to 6-week trials
Proportion of patients (%) | CAPLYTA (n=406) | Placebo (n=412) |
|---|---|---|
BARS | -0.1 | 0.0 |
AIMS | +0.1 | 0.0 |
SAS | +0.1 | 0.0 |
4- to 6-week trials
Proportion of patients (%) | CAPLYTA (n=372) | Placebo (n=374) |
|---|---|---|
BARS | -0.1 | 0.0 |
AIMS | +0.1 | 0.0 |
SAS | +0.1 | 0.0 |
In a 1-year open-label study, rates of akathisia and EPS with CAPLYTA were similar to the 4- to 6-week trials data. There were no increases from baseline in BARS, AIMS, or SAS scores1,2
*EPS (extrapyramidal symptoms) include akathisia, extrapyramidal disorder, muscle spasms, restlessness, musculoskeletal stiffness, dyskinesia, dystonia, muscle twitching, tardive dyskinesia, tremor, drooling, and involuntary muscle contractions.1
108 CAPLYTA patients completed at least one year of treatment.
†Barnes Akathisia Rating Scale (BARS) ranges from 0 to 14. The Abnormal Involuntary Movement Scale (AIMS) for dyskinesia (total score ranges from 0 to 28). The Simpson-Angus Scale (SAS) for EPS (total score ranges from 0 to 40). Movement scores represent mean change from baseline.
